# Avelumab/Gemcitabine in Sarcomatoid RCC

> **NCT03483883** · PHASE1 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 6 (actual)

## Conditions studied

- Metastatic sRCC

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03483883
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-19
- **Primary completion:** 2020-07-22
- **Final completion:** 2021-02-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study was terminated due to protracted accrual and limited patient engagement in the setting of rapidly changing treatment paradigms for advanced RCC with sarcomatoid features and/or intermediate/poor risk clinical features.
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03483883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03483883, "Avelumab/Gemcitabine in Sarcomatoid RCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03483883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*